Technical Analysis for FGEN - FibroGen, Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 4.06% | |
| Calm After Storm | Range Contraction | 4.06% | |
| NR7 | Range Contraction | 4.06% | |
| Narrow Range Bar | Range Contraction | 4.06% | |
| Inside Day | Range Contraction | 4.06% | |
| Calm After Storm | Range Contraction | 7.94% | |
| Narrow Range Bar | Range Contraction | 7.94% | |
| Inside Day | Range Contraction | 7.94% | |
| Gapped Up | Strength | 7.94% | |
| Fell Below 50 DMA | Bearish | 8.81% |
| Alert | Time |
|---|---|
| Upper Bollinger Band Resistance | 32 minutes ago |
| 60 Minute Opening Range Breakout | 42 minutes ago |
| Rose Above Upper Bollinger Band | 42 minutes ago |
| 50 DMA Resistance | about 2 hours ago |
| Up 5% | about 3 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/04/2024
FibroGen, Inc Description
FibroGen, Inc. operates as a research-based biopharmaceutical company in the United States. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Monoclonal Antibody Kidney Disease Pancreatic Cancer Anemia Idiopathic Pulmonary Fibrosis Chronic Kidney Disease Pulmonary Fibrosis Blindness Cornea Collagen Liver Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Hypoxia Inducible Factors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.93 |
| 52 Week Low | 0.18 |
| Average Volume | 1,249,132 |
| 200-Day Moving Average | 1.03 |
| 50-Day Moving Average | 0.36 |
| 20-Day Moving Average | 0.33 |
| 10-Day Moving Average | 0.34 |
| Average True Range | 0.04 |
| RSI (14) | 51.22 |
| ADX | 24.85 |
| +DI | 14.08 |
| -DI | 25.43 |
| Chandelier Exit (Long, 3 ATRs) | 0.29 |
| Chandelier Exit (Short, 3 ATRs) | 0.31 |
| Upper Bollinger Bands | 0.37 |
| Lower Bollinger Band | 0.28 |
| Percent B (%b) | 0.75 |
| BandWidth | 27.48 |
| MACD Line | 0.00 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.0056 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.39 | ||||
| Resistance 3 (R3) | 0.39 | 0.37 | 0.38 | ||
| Resistance 2 (R2) | 0.37 | 0.36 | 0.37 | 0.38 | |
| Resistance 1 (R1) | 0.36 | 0.36 | 0.36 | 0.36 | 0.38 |
| Pivot Point | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 |
| Support 1 (S1) | 0.34 | 0.34 | 0.33 | 0.34 | 0.32 |
| Support 2 (S2) | 0.32 | 0.33 | 0.32 | 0.32 | |
| Support 3 (S3) | 0.31 | 0.32 | 0.32 | ||
| Support 4 (S4) | 0.31 |
